the list of acetonitrile, proprionitrile, acetone, methanol, ethanol, toluene and xylenes (ortho, meta or para) or a mixture thereof, at a temperature below 60°C with polymorphic form III of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride;

b. capturing polymorphic form III of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride.

7. A process for preparing polymorphic form III of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride comprising:

a. adding polymorphic I, form II, amorphous or a mixture of the forms of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride to an organic solvent selected from the list of acetonitrile, proprionitrile, acetone, methanol, ethanol, heptane, toluene and xylenes (ortho, meta or para) or a mixture thereof, at a temperature below 60°C to produce a suspension;

b. seeding with polymorphic form III of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride at a temperature below 60°C;

c. capturing polymorphic form III of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride.

8. The process according to claim 7, wherein the organic solvent is a mixture of acetone and heptane in the ratio 1:4.

9. The process according to any of the claim 4-7, wherein the organic solvent is a mixture of methanol and toluene in the ratio 1:4.

10. A compound according to any of the claims 1-3 or 15 for use as a medicament.

11. A pharmaceutical composition comprising a compound according to any of the claims 1-3 or 15.